Key Takeaways
- Eli Lilly claims Foundayo demonstrates superior performance compared to Novo Nordisk’s oral Ozempic in type 2 diabetes treatment.
- The 17.2 mg dose of Foundayo achieved up to 2% greater weight reduction than the 25 mg Ozempic pill.
- Novo Nordisk’s high-dose oral Ozempic has not received US approval for type 2 diabetes; FDA approval is anticipated by late 2026.
- Eli Lilly also published data indicating Zepbound’s higher doses surpass Novo’s Wegovy HD in weight management.
- The 15 mg dose of Zepbound produced approximately 5% additional weight loss compared to Wegovy HD.
Eli Lilly has taken an aggressive stance in the competitive diabetes and obesity drug market. The pharmaceutical giant unveiled fresh clinical data this week positioning its medications as superior alternatives to Novo Nordisk’s offerings.
The announcement came Tuesday when Lilly declared that Foundayo demonstrates stronger performance than Novo’s oral Ozempic formulation in treating adults with type 2 diabetes. This assertion stems from an indirect statistical comparison rather than a direct clinical trial.
The pharmaceutical company analyzed results from two distinct late-stage clinical trials to draw its conclusions. Researchers examined outcomes between Foundayo’s 17.2 mg formulation and Novo’s 25 mg oral semaglutide tablet.
The findings revealed that Foundayo produced up to 2% additional weight reduction compared to the higher-strength Ozempic pill. Lilly’s analysis also indicated slightly improved glycemic control with its medication.
The 25 mg oral Ozempic formulation has yet to secure US regulatory approval for type 2 diabetes treatment. The FDA is scheduled to make its determination before the conclusion of 2026.
Novo Nordisk Responds
Novo Nordisk swiftly countered Lilly’s claims. A company representative informed Reuters that the analysis centered on diabetes patients rather than individuals seeking obesity treatment.
This differentiation carries significant weight. Clinical research consistently demonstrates that diabetic patients experience less substantial weight reduction compared to those receiving treatment exclusively for weight management.
Both oral Ozempic and Foundayo are classified as GLP-1 receptor agonists. This medication category functions by managing glucose levels and reducing hunger signals.
Injectable Comparison: Zepbound Takes On Wegovy HD
Lilly extended its comparative analysis beyond diabetes medications. The company simultaneously published findings comparing its injectable medication Zepbound against Novo’s high-strength Wegovy formulation.
The evaluation examined Zepbound doses of 10 mg and 15 mg versus Wegovy HD across a 72-week treatment period. These injectable therapies represent leading options in the obesity treatment market.
Individuals receiving Zepbound 15 mg experienced approximately 5% greater average body weight reduction than Wegovy HD recipients. The 10 mg dose produced roughly 3% additional weight loss.
According to Lilly’s findings, patients administered the 15 mg dose achieved triple the likelihood of reaching 20% or greater total body weight loss compared to Wegovy HD users. Treatment discontinuation due to adverse effects remained comparable across all three dosage groups.
The comparative analysis drew from Lilly’s SURMOUNT-1 clinical trial and Novo’s STEP UP research programs. These large-scale studies included thousands of participants with elevated body weight or obesity across multiple continents.
Lilly shared these results during the European Association for the Study of Diabetes annual conference. Rachel Batterham, serving as Lilly’s senior vice president of medical innovation, acknowledged that direct comparative trials provide optimal evidence, though indirect statistical analyses deliver valuable insights when head-to-head studies are unavailable.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
